Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
reMYND NV today announced that its shareholders have elected Ajit Shetty to join the company’s 4-person Board as an Independent Director.
Ajit Shetty commented: “It is an honour to be elected as a member of reMYND’s Board of Directors. reMYND is a great example of a successful spin-off from a great university (KULeuven), adding transformational value to solving healthcare problems challenging today’s world. It is indeed a privilege to work with a remarkable Board to build a sustainable platform for the future success of reMYND.”
Paul Van Dun, Chairman of reMYND said: “We are delighted to welcome Ajit to our board. He brings a wealth of experience in pharma and life sciences, and his expertise will be an extremely valuable addition to reMYND”.
Rudy Dekeyser, Independent Director of reMYND said: “reMYND has gone through a nice evolution over the last years: in addition to expanding its CRO-activities, the company has been able to develop candidate treatments for important disorders, such as Alzheimer’s disease and Parkinson’s disease. This provides reMYND many perspectives for the near future, and the personality, experience and network of Ajit will be very valuable in making the right choices”.
Koen De Witte, Managing Director of reMYND said: “This is fantastic news for reMYND. After an introduction by Herman Daems, Ajit has been a mentor to me for the last two years. With Ajit, Paul, and Rudy, we have now an exceptional board covering expertise ranging from fundamental research to bringing products to the FDA and having them produced, from as well a biotech as large pharma perspective. All directors have consistently focused on what is best for reMYND in the long-term. The toughest discussion we had so far was to convince our independent directors to accept some remuneration for all their efforts and almost weekly contacts …”.
Ajit Shetty had a very exciting and fulfilling career culminating as the Chairman of Janssen Pharmaceutica Belgium as well as the Corporate VP for the Enterprise Supply Chain of Johnson & Johnson, the world’s largest healthcare company.
Ajit has held various functional responsibilities and was a major team player in helping to build the Janssen global network of companies as well as establishing the platform for Janssen USA.
Ajit has an MA-PhD degree from Cambridge University (UK) and an MBA from Carnegie-Mellon University (USA).
In addition, Ajit is a Board member of Soudal NV and a member of the Board of Trustees for Carnegie-Mellon University. He is also a member of the Corporate Advisory Board for the Carey Business School at Johns Hopkins University (USA).
reMYND, a spin-off company of Leuven University, Belgium, actively drives the development of disease-modifying treatments, both through its own Drug Discovery & Development and as a Contract Research Organization (CRO):